Core for Life - a new European alliance in biomedical research: http://t.co/Hvv6P88kRt
FlandersBio informs you about important regional and national life sciences news. Send us your news. If your news is of interest to the life sciences community, we will post it on our website.
FlandersBio informeert u over belangrijk nieuws op het vlak van de biowetenschappen. Bezorg ons jouw nieuwtjes. Als het interessant is voor de sector, zullen wij het op onze website plaatsen.
Cryo-Save Group N.V. (Euronext: CRYO, 'Cryo-Save', or 'the Group'), the leading international stem cell storage company and the largest family stem cell bank in Europe, is happy to welcome Ms. Karin Dorrepaal, PhD, MBA as its new Non-Executive Director.
Ms. Dorrepaal has been appointed at Cryo-Save's Annual General Meeting held on May 16, 2012.
After obtaining her PhD in medicine at the Free University of Amsterdam on a study executed in the Netherlands Cancer Institute and earning an MBA, she joined Booz Allen & Hamilton (now Booz & Co.) to become Vice President focusing on the pharmaceutical industry and advising clients on issues regarding strategy, sales, marketing and supply chain. Subsequently she served on the Executive Board of Schering AG in Berlin, where she was responsible for the Diagnostic Imaging business (turnover EUR 1,3 billion) as well as for supply chain and procurement. With her broad experience and strong external network within the industry, Ms. Dorrepaal will be a valuable addition to the Cryo-Save Board of Directors.
Ms. Dorrepaal served as a Non-Executive Director on the corporate boards of Ergo Versicherungsgruppe AG and the Hogeschool van Amsterdam/ University of Amsterdam. Currently she serves as a Non-Executive Director of MDxHealth SA in Belgium, as a member of the Triton Private Equity Industry Board in Frankfurt and as a member of the Supervisory Board of Gerresheimer AG in Düsseldorf.
Arnoud van Tulder, Chief Executive Officer, commented: "I am very glad to welcome Ms. Dorrepaal as a new Non-Executive Director. Her solid international experience will be an important asset to the Board in its continuous guidance and supervision of the strategic development of Cryo-Save."
Cryo-Save, the leading international family stem cell bank, stores more than 200,000 samples from umbilical cord blood, cord tissue and adipose tissue. There are already many diseases treatable by the use of stem cells, and the number of treatments will only increase. Driven by its international business strategy, Cryo-Save is now represented in over 40 countries on 3 continents, with ultra-modern processing and storage facilities in Belgium, Germany, Dubai, India, South Africa and France (validation in progress).
Source: Cryo-Save Group